New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RHHBY From The Last 14 Days
Check below for free stories on RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
06:18 EDTRHHBYEMA warns that stolen Roche drug found on market
The European Medicines Agency has been informed that vials of the cancer medicine Herceptin, thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries. This is currently being investigated by Member State authorities and updates will be provided as more information becomes available. Italian law enforcement authorities are currently investigating the theft and are looking at whether other medicines may also be affected. No affected product has so far been identified at hospital level and there are no reports that any harm has come to patients in relation to the falsified medicine and authorities are working to avoid this. The marketing authorisation holder for Herceptin is Roche.
April 16, 2014
07:32 EDTRHHBYRegeneron may be taking market share from Roche, says Brean Capital
Subscribe for More Information
April 15, 2014
09:02 EDTRHHBYRoche confirms FY outlook for low-to mid-single digit growth in sales
Subscribe for More Information
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: “Both the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
08:23 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTRHHBYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 10, 2014
11:42 EDTRHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
April 8, 2014
16:10 EDTRHHBYProthena says first human dosed in Phase 1 study of PRX002
Prothena (PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15M milestone payment from Roche (RHHBY) related to the initiation of this study. The initial Phase 1 clinical trial of PRX002 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects. It is designed to assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity. As previously announced in December 2013, Prothena entered into a worldwide collaboration with Roche to develop and commercialize antibodies that target α-synuclein, including PRX002. Including the current milestone payment, Prothena has now achieved a total of $45M through its worldwide PRX002 collaboration with Roche.
11:03 EDTRHHBYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 7, 2014
06:07 EDTRHHBYRoche acquires IQuum for $450M
Subscribe for More Information
April 3, 2014
10:03 EDTRHHBYRoche unit signs companion diagnostic agreement with Genmab
Ventana Medical Systems, a member of the Roche Group, announced that it has entered into an agreement with Genmab A/S for the development of companion diagnostic tools for Genmab's HuMax-TF-ADC antibody drug conjugate program. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF-ADC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use